tetano
Editor, Senior Moderator
J Infect Chemother
. 2023 Mar 29;S1341-321X(23)00079-X.
doi: 10.1016/j.jiac.2023.03.018. Online ahead of print.
The first case of clade I Candida auris candidemia in a patient with COVID-19 in Japan
Yusuke Ohashi[SUP] 1 [/SUP], Takashi Matono[SUP] 2 [/SUP], Shotaro Suzuki[SUP] 3 [/SUP], Shumpei Yoshino[SUP] 3 [/SUP], Mohamed Mahdi Alshahni[SUP] 4 [/SUP], Aya Komori[SUP] 4 [/SUP], Koichi Makimura[SUP] 4 [/SUP]
Affiliations
Abstract
Candida auris is a health hazard because of its antifungal resistance and the potential to cause healthcare-associated outbreaks. To our knowledge, no previous cases of candidemia caused by C. auris have been reported in Japan. Herein, we report the first known case of clade I C. auris candidemia in a Japanese man with coronavirus disease 2019 (COVID-19) infection who was medically evacuated from the Philippines. A 71-year-old Japanese man traveled to Cebu Island in the Philippines 5 months before admission to our hospital. He contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Philippines and was admitted to the intensive care unit (ICU) in a local hospital. During his medical evacuation, we implemented precautions given his history of COVID-19 and pneumonia caused by multi-drug-resistant Acinetobacter baumannii complex. His blood culture revealed that C. auris infection was treated with antifungal agents but he did not survive. No evidence of nosocomial transmission was found among other patients in the ICU. This case study determines that accurate detection of C. auris, appropriate antifungal agent selection, precautions, and patient isolation are crucial to prevent nosocomial outbreaks, especially in patients with a history of multidrug-resistant organism (MDRO) colonization or international hospitalization. Medical professionals should recognize the risk of MDROs in international medical evacuation settings, considering the recent resumption of cross-border travel after the COVID-19 pandemic.
Keywords: Antifungal resistance; COVID-19; Candida auris; Candidemia.
. 2023 Mar 29;S1341-321X(23)00079-X.
doi: 10.1016/j.jiac.2023.03.018. Online ahead of print.
The first case of clade I Candida auris candidemia in a patient with COVID-19 in Japan
Yusuke Ohashi[SUP] 1 [/SUP], Takashi Matono[SUP] 2 [/SUP], Shotaro Suzuki[SUP] 3 [/SUP], Shumpei Yoshino[SUP] 3 [/SUP], Mohamed Mahdi Alshahni[SUP] 4 [/SUP], Aya Komori[SUP] 4 [/SUP], Koichi Makimura[SUP] 4 [/SUP]
Affiliations
- PMID: 37001753
- DOI: 10.1016/j.jiac.2023.03.018
Abstract
Candida auris is a health hazard because of its antifungal resistance and the potential to cause healthcare-associated outbreaks. To our knowledge, no previous cases of candidemia caused by C. auris have been reported in Japan. Herein, we report the first known case of clade I C. auris candidemia in a Japanese man with coronavirus disease 2019 (COVID-19) infection who was medically evacuated from the Philippines. A 71-year-old Japanese man traveled to Cebu Island in the Philippines 5 months before admission to our hospital. He contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Philippines and was admitted to the intensive care unit (ICU) in a local hospital. During his medical evacuation, we implemented precautions given his history of COVID-19 and pneumonia caused by multi-drug-resistant Acinetobacter baumannii complex. His blood culture revealed that C. auris infection was treated with antifungal agents but he did not survive. No evidence of nosocomial transmission was found among other patients in the ICU. This case study determines that accurate detection of C. auris, appropriate antifungal agent selection, precautions, and patient isolation are crucial to prevent nosocomial outbreaks, especially in patients with a history of multidrug-resistant organism (MDRO) colonization or international hospitalization. Medical professionals should recognize the risk of MDROs in international medical evacuation settings, considering the recent resumption of cross-border travel after the COVID-19 pandemic.
Keywords: Antifungal resistance; COVID-19; Candida auris; Candidemia.